Impact of Sleep Deprivation and Caffeine in Medical Professionals

Exploring the Impact of Sleep Deprivation and Caffeine on Operationally Relevant Complex Cognitive Processes in Medical Professionals

While the negative impact of sleep deprivation on cognitive processing and the partial reversal of this phenomenon by caffeine are well known, the types of cognitive processing previously studied have been limited to simple, straight-forward laboratory tasks. It is unclear how sleep deprivation and caffeine affect performance on operationally relevant complex cognitive tasks, like those encountered by working professionals such as doctors. This study aims to uncover how sleep deprivation and caffeine impact two types of clinical reasoning processes encountered by physicians on a daily basis. Previous work from members of our team investigated diagnostic reasoning in medical professionals and discovered that brain activation in executive processing areas was modulated by self-reported sleepiness and burnout and level of expertise (Durning, Costanzo, et al., 2013; Durning et al., 2014, 2015). The current study aims to expand upon those findings by also investigating a potentially more complex type of clinical reasoning, i.e. therapeutic reasoning, and directly manipulating sleep and caffeine use in a controlled sleep laboratory. Medical students, residents, and board-certified physicians will undergo thirty-seven hours of sleep deprivation and ten hours of sleep recovery in the sleep laboratory. During two FMRI scan sessions we will present high-quality validated multiple-choice questions on common patient situations in internal medicine to participants to explore brain activity during therapeutic reasoning compared with diagnostic reasoning. One FMRI scan will occur following a night of sleep deprivation, and another scan will occur following a night of recovery sleep. Additionally, half of the participants will receive caffeine gum during the sleep deprivation period, while the other half will receive placebo gum. This design will allow us to study the effect of sleep deprivation and caffeine on the neural correlates of diagnostic and therapeutic reasoning and performance in general.

Study Overview

• Status: Active, not recruiting
• Conditions: Performance; Sleep Deprivation
• Intervention / Treatment: Dietary supplement: Military Energy Gum; Dietary supplement: Placebo Gum

• Study Type: Interventional
• Enrollment (Anticipated): 42
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Silver Spring, Maryland, United States, 20910
      • WRAIR Sleep Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Novice group --National Capital Area Interns and Medical Students (3rd and 4th year only)
2. Intermediate group - National Capital Area PGY-2 and 3 residents in internal medicine
3. Expert group-Board certified internists from National Capital Area

Exclusion Criteria:

Related to Sleep Research Center. The following exclusion criteria apply to all volunteers:

• Self-reported habitual nightly sleep amounts outside the target range of 6-9 hours (i.e., less than 6 hours per night or more than 9 hours per night, on average) (Post-consent Checklist)
• Self-reported nighttime lights-out times earlier than 2100 hours on average during weeknights (Sunday through Thursday) (Post-consent Checklist)
• Self-reported morning wake-up times later than 0900 on average during weekdays (Monday through Friday) (Post-consent Checklist)
• Self-reported habitual napping (> 4 time a week in conjunction with normal sleep habits) (Post-consent Checklist)
• Self-reported caffeine use in excess of 400 mg (e.g., approximately 8 caffeinated sodas or 4 12-oz cups of coffee) per day on average (Post-consent Checklist; document provides exclusionary limits for various caffeinated products).
• Score of lower than 31 or higher than 69 on the Morningness-Eveningness Questionnaire (MEQ form)
• Score of 14 or above on the Beck Inventory Form (BDI form)
• Score of 41 or above on the Spielberger Trait Anxiety Inventory
• History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction) (Medical History and Examination Form)
• History of neurologic disorder (to include, but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders) (Medical History and Examination form; sleep items on Post-Consent Checklist)
• Underlying pulmonary disease requiring daily inhaler use (Medical History and Examination form)
• Kidney disease or kidney abnormalities (Medical History and Examination form, laboratory results)
• Liver disease or liver abnormalities (Medical History and Examination form, laboratory results)
• Self-reported history of psychiatric disorder requiring hospitalization or psychiatric product for any length of time (Medical History and Examination form)
• Self-reported or suspected regular nicotine use or addiction, defined as more than 1 cigarette or equivalent per week, within the last 1 year (Medical History and Examination form)
• Self-reported or suspected heavy alcohol use; minimum limit to define heavy alcohol use is 14 drinks per week or as determined by the examining study licensed physician (Medical History and Examination form)
• Self-reported or suspected use of products or drugs that cannot be safely discontinued during in-laboratory phases, to be determined on a case-by-case basis by the examining study licensed physician (Medical History and Examination form)
• Self-reported or suspected current use of other illicit drugs, to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana (Medical History and Examination form)
• Positive urine pregnancy result
• Female volunteers who are breastfeeding, lactating, or actively trying to conceive
• Resting blood pressure above 140/90 or resting pulse > 110 (Medical History and Examination form). Note that if a repeat measurement is within range then the volunteer will not be excluded.
• BMI ≥ 30 (Obese Class I or greater) (Medical History and Examination form)
• Clinically significant values (as determined by the reviewing study licensed physician) for any hematology or chemistry parameter. Reviewing physician may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant.
• Positive urine nicotine/cotinine result during screening visit (NicCheck™ I test strip results)
• Positive urine drug result during screening visit
• Any use of prescription or over-the-counter sleep aids during the 6 month period prior to screening indicative of a potential sleep disorder as determined by the examining study medical investigator [e.g., use of a sleep aid for several nights following time zone travel, or the occasional use of a sleep inducing medication (e.g. 1-2 times per month), would not necessarily constitute evidence of a sleep disorder and result in disqualification].
• Not fitting into one of four categories: 1) 3rd of 4th year medical student AND native English speaker, 2) medical intern, 3) PGY-2 or PGY-3 resident in internal medicine, 4) board-certified internist (Post-consent checklist)
• Inability to read and sign the consent and HIPAA authorization form
• Active duty military or federal personnel: not off duty and not on approved annual leave for the enrollment visit as well as the in-laboratory phase of the study

Related to FMRI task.

The following exclusion criteria apply to all subjects (MR Safety Screening form):

• The presence of incompatible shrapnel or implanted devices
• A history of prior inability to complete an MRI scan due to anxiety or claustrophobia (participants will not be able to take benzodiazepines or other sedatives prior to the scan to treat anxiety, as these would adversely impact thought processes).
• Being treated with calcium channel blocker medicines (because of the potential impact of such medicines on cerebral blood flow patterns).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Caffeine Group; This group will receive caffeine gum.	Dietary supplement: Military Energy Gum; Caffeine (1, 3, 7-trimethylxanthine) is a central nervous system stimulant that is found naturally in some foods and beverages such as coffee and tea. For this study, caffeine will be administered in the form of gum pellets (Military Energy chewing gum). Each pellet contains 100 mg of caffeine.
Placebo Comparator: Placebo; This group will receive gum without caffeine.	Dietary supplement: Placebo Gum; Pellet form placebo gum

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Psychomotor Vigilance Task	Computer Based response time measurement	5 days
Clinical Reasoning Questions	Answer clinical board questions	5 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Actigraphy	Wrist movement and activity monitoring	5 days
Polysomnography	Measurement of brain activity	5 days
Structural Brain Scan-functional MRI	Measurement of structural brain topography to localize areas of functional activation using a functional MRI scan	5 days

Collaborators and Investigators

• Sponsor: Walter Reed Army Institute of Research (WRAIR)

Study record dates

Study Major Dates

• Study Start (Actual): July 6, 2017
• Primary Completion (Anticipated): October 12, 2026
• Study Completion (Anticipated): October 12, 2028

Study Registration Dates

• First Submitted: September 5, 2019
• First Submitted That Met QC Criteria: February 17, 2020
• First Posted (Actual): February 18, 2020

Study Record Updates

• Last Update Posted (Actual): May 3, 2023
• Last Update Submitted That Met QC Criteria: April 28, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Dyssomnias; Sleep Wake Disorders; Neurologic Manifestations; Sleep Deprivation
• Other Study ID Numbers: WRAIR #2311

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No